NM_000329.3(RPE65):c.16G>T (p.Glu6Ter) is a frameshift variant that introduces a premature stop codon into exon 2 of 14, and is predicted to lead to nonsense-mediated decay in a gene in which loss-of-function is an established mechanism of disease (PVS1). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). At least one proband harboring this variant exhibits a phenotype including diagnosis with Leber congenital amaurosis (0.5 pts, PMID: 25257057) and significant, documented improvement of retinal sensitivity by dark-adapted perimetry and microperimetry after treatment with RPE65 gene therapy (8 pts, PMID: 25938638), which together are highly specific for RPE65-related recessive retinopathy (total 8.5 pts, PP4_Moderate). This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who harbored the variant in the compound heterozygous state with the NM_000329.3(RPE65):c.499G>T (p.Asp167Tyr) variant suspected but not confirmed in trans (PMID: 25257057). However, the proband was not counted for PM3 in order to avoid circularity. In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PVS1, PM2_Supporting, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).